News

A Kessler Foundation scientist has been awarded nearly $600,000 to support the development and testing of a behavioral therapy intervention aiming to improve quality of life for people with multiple sclerosis (MS). An upcoming clinical trial into the intervention (NCT05195320), expected to begin…

A new imaging technique called magnetic resonance spectroscopic imaging, or MRSI, could be useful for diagnosing and monitoring multiple sclerosis (MS), according to a small study. “If confirmed in longitudinal clinical studies, this new neuroimaging technique could become a standard imaging tool for initial diagnosis, for disease progression and…

Tecfidera (dimethyl fumarate) appears to have similar benefits to Gilenya (fingolimod) in preventing relapses and the loss of motor function and cognition in people with multiple sclerosis (MS), a study with real-world data found. The two medications also led to similar findings on MRI scans, including in…

Exergames — playing video games that involve physical exercise — may be more effective at improving balance in people with multiple sclerosis (MS) than conventional rehabilitation, a review of current studies suggested. The study, “Efficacy of Virtual Reality and Exergaming in Improving Balance in Patients With…

Cyxone will work with a European organization to scale up production of the active ingredient in T20K, its experimental treatment for multiple sclerosis (MS), the company announced. The collaboration, which will cover the development of a new manufacturing method and later the…

Differences in the physical architecture of the brain may explain why some people with multiple sclerosis (MS), but not others, experience a placebo effect, according to a new study. The results suggest that MS itself may make some individuals unable to experience the benefits of a placebo. “Our findings…

Acthar Gel (repository corticotropin injection) may be useful for managing disease relapses in people with relapsing-remitting multiple sclerosis (RRMS) who fail to respond to treatment with corticosteroids, according to results from a small clinical trial. The study, “Results from a multicenter, randomized, double-blind, placebo-controlled study…

It took some time for Tyler Campbell to truly accept he had relapsing-remitting multiple sclerosis. The San Diego State University running back had just finished his junior year in 2007 when his multiple sclerosis (MS) symptoms began. After an MRI confirmed the diagnosis, his neurologist cleared him to…

Long-term treatment with Gilenya (fingolimod) in routine clinical practice is safe and effective for relapsing-remitting multiple sclerosis (RRMS), a five-year study in Germany of more than 4,000 patients reported. Over time, relapses in the majority of study patients who continued with Gilenya became less common and less severe,…

Under rules in the No Surprises Act, insured patients people in the U.S., including those with multiple sclerosis, should no longer receive unexpected medical bills for emergency care or for treatment from out-of-network providers at facilities in their network. The act, which became effective on Jan. 1, prohibits…

The ENSURE-2 Phase 3 clinical trial, evaluating Immunic Therapeutics’ experimental oral therapy IMU-838 (vidofludimus calcium) in adults with relapsing-remitting multiple sclerosis (RRMS), has enrolled its first patient. The milestone, announced in an email to Multiple Sclerosis News Today, follows the recruitment of the first RRMS patient in…

Infection with the common Epstein-Barr virus (EBV) increases the risk of developing multiple sclerosis (MS) by 32 times — the strongest link yet — according to a study looking at two decades of data from more than 10 million U.S. military members. “The hypothesis that EBV causes MS has been…

Emerald Health Pharmaceuticals will soon begin enrollment in a Phase 2a clinical trial investigating its cannabidiol-derived therapy EHP-101 in relapsing forms of multiple sclerosis (MS). The trial (NCT04909502) aims to recruit 50 patients, ages 18-55, with relapsing-remitting MS (RRMS) and active secondary progressive MS (SPMS).

Among people with multiple sclerosis (MS), a progressive disease type and the use of anti-CD20 therapies — such as ocrelizumab and rituximab — were associated with an increased risk of death from COVID-19, a new meta-analysis revealed. “We hope that these findings … may help neurologists in optimizing…

Atara Biotherapeutics has partnered with Imeka to use its proprietary biomarker imaging technology in the ongoing EMBOLD Phase 2 clinical trial, which is investigating ATA188 for the treatment of progressive forms of multiple sclerosis (MS). The imaging technology will be used to determine if Atara’s ATA188…

People with multiple sclerosis (MS) are at greater risk of developing cancer than the general population, according to a French study involving nearly 100,000 patients. This increased risk was particularly apparent for prostate, breast, colorectal, and anal cancers, as well as cancers of the trachea, bronchus, and lung. The researchers…

Cognitive dysfunction in patients with multiple sclerosis (MS) is predictive of worse outcomes, including clinical progression of the disease and a higher risk of mortality, according to a new study. “This review revealed that cognitive dysfunction … was associated with higher odds of transitioning from [a] relapsing–remitting course to…

Following promising data from the first participant in a special access program that’s testing foralumab nasal spray for secondary progressive multiple sclerosis (SPMS), a second patient has been enrolled in the ongoing evaluation. The first patient in the study, by Tiziana Life Sciences, the nasal spray’s developer, was halfway through…

People with multiple sclerosis (MS) have high levels of toxic compounds made by gut bacteria in the fluid around their brain and spinal cord, a study found. “This work not only furthers our understanding of the role of gut-brain communication in neurodegenerative disease progression, but also provides a potential…

The U.S. Food and Drug Administration (FDA) has approved Abbott’s request to expand the magnetic resonance imaging (MRI) compatibility with its Proclaim XR spinal cord stimulation system with Octrode leads, which is used to manage chronic pain. The decision lifts previous restrictions for Octrode lead tip location and…

Ocrevus (ocrelizumab) may be more effective than Gilenya (fingolimod) at preventing relapse in relapsing-remitting multiple sclerosis (RRMS) patients who recently transitioned from Tysabri (natalizumab), according to a new study. Ocrevus is “potentially a better exit strategy than [Gilenya] after [Tysabri] cessation, with an impressive reduction [in] risk…

A Phase 1 clinical trial investigating the safety and tolerability of Anokion‘s ANK-700 in people with relapsing-remitting multiple sclerosis (RRMS) has begun enrolling patients for its multiple ascending dose part. This opening of the study’s second part follows positive safety signs in patients given the one of two doses of…

A decision by the U.S. Court of Appeals for the Federal Circuit has upheld the validity of a patent for dosing Novartis’ oral multiple sclerosis (MS) treatment Gilenya (fingolimod), the medication’s manufacturer announced. “With this decision, Novartis confirms that it expects no generic versions of Gilenya in the…

A new machine learning algorithm — designed to analyze healthcare records — could help in diagnosing multiple sclerosis (MS) sooner by identifying patients’ symptoms earlier. The algorithm, devised by scientists at the University of California San Francisco (UCSF), was described in a study titled “Embedding electronic health records…

The French Health Authority has approved AB Science’s request to launch a Phase 3 clinical trial to confirm the safety and effectiveness of its lead candidate masitinib in adults with primary progressive multiple sclerosis (PPMS) and nonactive secondary progressive MS (SPMS). “We are very excited to initiate…

Other autoimmune conditions, particularly those characterized by the presence of anti-TPO antibodies, should not preclude patients with multiple sclerosis (MS) from receiving treatment with Lemtrada (alemtuzumab), according to an analysis of pooled data from clinical trials and post-market data. The study, “Autoimmunity and long-term safety and efficacy…

Being a lifelong musician can help protect certain tracts of the brain’s white matter from damage during aging, potentially warding off conditions such as multiple sclerosis, Parkinson’s disease, or dementia for years. That’s according to the study “Effects of Lifelong Musicianship on White Matter Integrity…

Adults with multiple sclerosis (MS) and depression or anxiety, especially those of minority groups, are being asked to join a clinical trial assessing the benefits of eSupport Health’s online support group program, the National MS Society announced in a press release. The CONNECT study is particularly focused on Black and…

Multiple Sclerosis News Today brought you daily coverage of the latest scientific research, advances in treatment, and clinical trials related to multiple sclerosis (MS) throughout 2021. We look forward to continuing to be a resource for the MS community in 2022. Here are the Top 10 most-read articles of…

NervGen Pharma has received approval to begin testing multiple ascending doses of NVG-291, its lead therapeutic candidate for multiple sclerosis (MS) and other neurologic conditions, in a Phase 1 trial with healthy volunteers. This multiple ascending dose (MAD) part, in which participants will receive increasing doses of NVG-291…